NRD
TNGX icon

Nebula Research & Development’s Tango Therapeutics TNGX Stock Holding History

Nebula Research & Development’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-51,924
Closed -$160K – 1139
2024
Q4 		$160K Buy
51,924
+41,023
+376% +$190K 0.02% 833
2024
Q3 		$83.9K Buy
+10,901
New +$104K 0.01% 887

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nebula Research & Development's TNGX Position: Q1 2025 in Review

Nebula Research & Development sold out of Tango Therapeutics (TNGX) in Q1 2025, closing a stake of 51,924 shares — an estimated $160K sold.

Nebula Research & Development first reported a position in TNGX in Q3 2024 and held it in 2 quarters. The position peaked at $160K in Q4 2024. 122 funds tracked by Wall St. Rank hold TNGX as of Q1 2025.

  • Nebula Research & Development reported no remaining Tango Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Nebula Research & Development sold 51,924 Tango Therapeutics shares in Q1 2025, an estimated $160K.
  • Nebula Research & Development first reported a position in Tango Therapeutics in Q3 2024 and held it in 2 quarters.
  • Nebula Research & Development's Tango Therapeutics position peaked at $160K in Q4 2024.
  • 122 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2025.

Based on Nebula Research & Development's 13F filing for Q1 2025, filed 15 May 2025.